Lysogene S.A. (LYS.PA)
Lysogene S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Neuilly-sur-Seine, FR. The stock last traded at $0.28, up 0.00% on the session, giving a market capitalisation of $4.9M. Its beta of 0.91 implies it has historically moved less than the broad market.
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Lysogene S.A. is most often compared with the following Healthcare names: